Altimmune

ALT

Market cap $442M

Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.

Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

Altimmune delivered strong 48-week Phase IIb data for pemvidutide in MASH, supporting progression to Phase III. Pemvidutide showed durable, dose-dependent improvements in non-invasive fibrosis markers and consistent safety, with weight loss reaching 7.5% at 1.8 mg. Regulatory alignment for a Phase III trial targeting accelerated approval appears promising, with biopsy-based endpoints and a planned 2.4 mg dose.

Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide.

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune said on Friday its experimental drug improved signs of liver scarring and liver health after 48 weeks of treatment in a mid-stage study of patients with a serious fatty liver disease known as MASH.

Improvements observed in key  non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint

The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.